Skip to main content
. Author manuscript; available in PMC: 2019 Aug 1.
Published in final edited form as: Cancer Discov. 2018 Jun 7;8(8):972–987. doi: 10.1158/2159-8290.CD-17-1298

Figure 6. SmarT-cells remain selective even upon secondary tumor rechallenge.

Figure 6

Panel (a) shows a schematic and representative image of NSG mice engrafted with 5×106 CAPAN1 PSCA+TGFβ+IL4 (right flank) and treated with FFluc+ SmarT-cells. Overlay of SmarT-cell signal detected by bioluminescence imaging and tumor volume using calipers (mean±SEM, n=7) (b) Schematic and representative image of tumor rechallenge model – mice engrafted with targets expressing antigen only (left shoulder, Ls) and pancreatic tumor signature (right shoulder, Rs). Superimposition of SmarT-cell signal against tumor volume for targets expressing PSCA only (top panel) or PSCA/TGFβ/IL4 (bottom panel).